Tafenoquine Succinate

琥珀酸他非诺喹

Report date: 2026/03/20 20:03:07
NME

Base Information

Drug NameTafenoquine Succinate
Drug Alias Name他非诺喹EtaquinetafenoquinaTafenoquinetafenoquinum +[13] 
ClassificationSmall molecules > Heterocyclic drugs > Antibiotics > Aminoquinoline antibiotics
Mechanisms of ActionElectron transport complex III inhibitorsReactive oxygen species stimulantsVirus replication inhibitors
TargetsElectron transport complex IIIReactive oxygen species
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Malaria, VivaxMalaria +[5] 
Global Approved IndicationsMalaria, Vivax
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2018/07/20
Country/TerritoryUnited StatesVietnamThailand +[9] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesWalter Reed Army Institute
China Registration ClassN/A

Develop Information

Active Companies60 Degrees Pharmaceuticals Inc60P Australia Pty Ltd60 Degrees Pharmaceuticals Llc +[6] 
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)Malaria, VivaxMalaria +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeP01BA07
Related LinksWikipediaDrugBankKEGG